A money manager at Carl Icahn’s investment firm is suing Bausch + Lomb Corp. and his billionaire employer, alleging he was ...

Bausch + Lomb's stock remains a "Hold" despite the latest financial results. Here's what investors need to keep in mind.

Bausch + Lomb recently allocated a US$2.80 billions tranche of new term B loans to refinance existing facilities, lowering interest margins and extending some maturities to January 15, 2031. Analyst ...

Shares of eyecare company Bausch + Lomb (NYSE:BLCO) jumped 2.2% in the morning session after Citigroup upgraded its rating on ...

Brent Saunders returned to Bausch + Lomb in 2023 to help address unmet needs in eye care, focusing on innovation and ...

Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb" or the "company"), a leading global eye health company dedicated to helping people see better to live better, today announced that it ...

Bausch + Lomb refinances $2.8B in loans, lowering interest rates and extending maturity to 2031. Learn how this move impacts BLCO’s financial outlook.

Issuing a largely positive outlook on the MedTech sector for 2026, Citi on Thursday upgraded Penumbra (PEN) and Bausch + Lomb ...

VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, issued the following statement ...

Bausch + Lomb, a company that started as a small optical goods shop in upstate New York and grew to become a global ophthalmic products business, is returning to the public markets. The company has ...

New York Gov. Andrew Cuomo said 200 employees notified now%3B another 200 to be laid off in %2714 Local officials had urged Valeant not to cut Bausch + Lomb%27s workforce Bausch + Lomb%27s ...

Shares of eyecare company Bausch + Lomb (NYSE:BLCO) jumped 4.2% in the morning session after Morgan Stanley upgraded its ...